Syngene International Limited specializes in delivering integrated scientific solutions spanning research, development, and manufacturing for the pharmaceutical, biotechnology, and other sectors.

Syngene secured its first global phase III clinical trial contract from a U.S. biotech company, reflecting its growing influence in the global clinical trials market, with strategic partnership expansions in multiple continents.

The company is expanding its biologics capabilities with a new GMP bioconjugation suite in Bengaluru, aimed at accelerating antibody drug conjugate development timelines.

Syngene achieved the highest level 'Green Certification' with a score of over 94% from My Green Lab, reinforcing its commitment to sustainability and positioning it among the top global companies for sustainability practices.

Despite revenue growth challenges, the company's strategic investments in new facilities and expansion into new markets indicate a strong focus on future growth and operational scale.